SCHEDULE: Quick Capital Discloses 9.9% Stake in Regen BioPharma
Beneficial Ownership Disclosure
Quick Capital, LLC has reported a 9.9% beneficial ownership stake in Regen BioPharma, Inc.'s common stock, holding 3,320,000 shares.
Summary
- Quick Capital, LLC, a Wyoming-based entity, has filed a Schedule 13G disclosing beneficial ownership of 3,320,000 shares of Common Stock in REGEN BIOPHARMA, INC.
- This ownership represents 9.9% of the outstanding shares of REGEN BIOPHARMA, INC.'s Common Stock.
- Quick Capital, LLC holds sole voting power and sole dispositive power over all 3,320,000 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the disclosure of a new significant investor, especially one certifying a passive investment, typically indicates confidence in the company's value or future potential. This can be viewed as a vote of confidence from an external entity.
Positives
- The disclosure of a significant 9.9% stake by Quick Capital, LLC may signal increased investor confidence in Regen BioPharma, Inc.'s future prospects.
- The passive nature of the investment, as certified by Quick Capital, LLC, suggests a long-term holding strategy rather than an activist intent.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investor, which is a common occurrence in the public markets. It does not provide specific insights into broader industry trends but rather reflects an investment decision in a particular biopharma company.
Stakeholder Impact
- Shareholders may perceive this as a positive signal, potentially leading to increased investor confidence and interest in the stock.
- The company's management might view this as validation of their strategy or asset value.
Key Dates
| Date | Description |
|---|---|
| 09/10/2025 | Date of event which requires the filing of this statement (acquisition of beneficial ownership). |
| 09/12/2025 | Date the Schedule 13G was signed by Eilon Natan, Managing Member of Quick Capital, LLC. |
Keywords
Regen BioPharma, Quick Capital, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.